Clinical Trial Update: Trial to Evaluate Safety and Tolerability of GP-2250 in Combination With Gemcitabine [Phase 1]

View source ↗

Summary

Phase 1 trial update on GP-2250 in combination with gemcitabine for pancreatic cancer; the study status is active and not recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pancreatic Cancer

Drugs mentioned

• GP-2250
• Gemzar (gemcitabine)

Snippet

Sponsor: Geistlich Pharma AG | Conditions: Pancreatic Cancer, Adult | Phase 1 | Status: ACTIVE_NOT_RECRUITING